**Serum soluble P-cadherin levels in the patients with ovarian tumors depending on their clinical and morphological characteristics**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Median sP-cadherin level, ng/mL** | **P value** |
| Age: |  |  |
| ≤ 57 years | 4.47 [2.59; 14.95] | 0.070 |
| > 57 years | 12.74 [4.21; 21.63] |  |
| Tumor histology: |  |  |
| Serous | 8.52 [3.26; 16.70] | 0.450 |
| Others | 3.35 [1.79; 21.40] |  |
| Stage: |  |  |
| I–II | 8.15 [3.29; 14.84] | I–II vs III > 0.999 |
| III | 7.59 [2.59; 17.36] | I–II vs IV > 0.999 |
| IV | 7.97 [4.07; 24.93] | III vs IV = 0.979 |
| Tumor size: |  |  |
| T1–T2 | 6.81 [2.62; 14.17] | 0.479 |
| T3–T4 | 8.05 [3.01; 19.00] |  |
| Regional metastases: |  |  |
| N0 | 6.60 [3.18; 15.95] | 0.725 |
| N+ | 10.08 [2.20; 25.83] |  |
| Distant metastases: |  |  |
| M0 | 8.59 [3.07; 16.55] | 0.669 |
| M+ | 7.50 [2.81; 24.03] |  |
| Malignancy grade: |  |  |
| Low | 14.02 [3.35; 24.14] | 0.507 |
| High | 8.52 [3.09; 16.20] |  |
| Ascitis: |  |  |
| А- | 11.83 [3.65; 17.41] | 0.944 |
| А+ | 9.57 [2.44; 25.89] |  |
| Location: |  |  |
| Unilateral | 12.87 [4.04; 25.89] | 0.820 |
| Bilateral | 11.11 [2.95; 19.00] |  |

S, soluble form